Payment overview · 2025
General Payments
$103.55
6 reported records · 6 companies
Healthcare provider profile · identity verified
Lwin Moe Win, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BARNEVELD, NY · NPI 1912119595
Verified facts
What the public records show
CMS Open Payments records show Lwin Moe Win, MD received $103.55 in general payments during 2025 across 6 reported records.
Lilly USA, LLC accounted for 22.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.12 | 22.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.83 | 19.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.92 | 17.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $14.59 | 14.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.58 | 14.1% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.51 | 13.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $103.55 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $23.12 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.83 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.92 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 2 Normalized: freestyle libre 2 |
Device | Abbott Laboratories | $14.59 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.58 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.58 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $13.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 42 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
40 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
42 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
147 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 670 | 192 |
| Omeprazole | Omeprazole | 461 | 121 |
| Levothyroxine Sodium | Levothyroxine Sodium | 451 | 105 |
| Lisinopril | Lisinopril | 345 | 105 |
| Amlodipine Besylate | Amlodipine Besylate | 343 | 97 |
| Metformin Hcl | Metformin Hcl | 287 | 85 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 258 | 88 |
| Gabapentin | Gabapentin | 237 | 50 |
| Losartan Potassium | Losartan Potassium | 233 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 193 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 193 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 192 | 53 |
| Alprazolam | Alprazolam | 186 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 180 | 33 |
| Furosemide | Furosemide | 173 | 60 |
| Simvastatin | Simvastatin | 172 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 154 | 46 |
| Famotidine | Famotidine | 149 | 42 |
| Ozempic | Semaglutide | 147 | 27 |
| Sertraline Hcl | Sertraline Hcl | 132 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 124 | 32 |
| Montelukast Sodium | Montelukast Sodium | 120 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 118 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 115 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 115 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 114 | 29 |
| Eliquis | Apixaban | 109 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 103 | 31 |
| Potassium Chloride | Potassium Chloride | 100 | 29 |
| Atenolol | Atenolol | 97 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 28 |
| Carvedilol | Carvedilol | 86 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 86 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 82 | 22 |
| Tramadol Hcl | Tramadol Hcl | 81 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 79 | 20 |
| Glipizide Er | Glipizide | 78 | 19 |
| Trazodone Hcl | Trazodone Hcl | 77 | 18 |
| Prednisone | Prednisone | 76 | 52 |
| Lovastatin | Lovastatin | 74 | 30 |
| Meloxicam | Meloxicam | 74 | 23 |
| Oxycodone Hcl | Oxycodone Hcl | 74 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 72 | 20 |
| Buspirone Hcl | Buspirone Hcl | 69 | 16 |
| Metformin Hcl Er | Metformin Hcl | 69 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 68 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 68 | 11 |
| Allopurinol | Allopurinol | 66 | 20 |
| Xarelto | Rivaroxaban | 60 | 21 |
| Clonazepam | Clonazepam | 55 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 53 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 52 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 52 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 52 | 13 |
| Glimepiride | Glimepiride | 51 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | 12 |
| Glipizide | Glipizide | 49 | 12 |
| Topiramate | Topiramate | 49 | 11 |
| Lactulose | Lactulose | 47 | suppressed |
| Ramipril | Ramipril | 46 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 45 | suppressed |
| Mirtazapine | Mirtazapine | 45 | suppressed |
| Bupropion Xl | Bupropion Hcl | 44 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | suppressed |
| Trulicity | Dulaglutide | 43 | suppressed |
| Jardiance | Empagliflozin | 42 | 15 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 41 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | 15 |
| Synthroid | Levothyroxine Sodium | 40 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 39 | 11 |
| Torsemide | Torsemide | 39 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Ezetimibe | Ezetimibe | 38 | suppressed |
| Ibuprofen | Ibuprofen | 38 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 18 |
| Finasteride | Finasteride | 37 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 37 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 37 | suppressed |
| Lorazepam | Lorazepam | 36 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 35 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 27 |
| Nystatin | Nystatin | 34 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 33 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Fenofibrate | Fenofibrate | 32 | suppressed |
| Rybelsus | Semaglutide | 32 | suppressed |
| Naproxen | Naproxen | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 30 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Valsartan | Valsartan | 29 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 28 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Celecoxib | Celecoxib | 27 | suppressed |
| Diazepam | Diazepam | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 15 |
| Niacin Er | Niacin | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Scopolamine | Scopolamine | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 21 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Tradjenta | Linagliptin | 24 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Epinephrine | Epinephrine | 20 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Calcitriol | Calcitriol | 19 | suppressed |
| Carbamazepine | Carbamazepine | 19 | suppressed |
| Levemir Flexpen | Insulin Detemir | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 11 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 18 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 12 |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Captopril | Captopril | 13 | suppressed |
| Colchicine | Colchicine | 13 | 11 |
| Fluconazole | Fluconazole | 13 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 13 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Hydrocodone-Ibuprofen | Hydrocodone/Ibuprofen | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | 11 |
| Desmopressin Acetate | Desmopressin Acetate | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $103.55 · 6 records | Lilly USA, LLC | Auvelity, FREESTYLE LIBRE 2, JARDIANCE, QULIPTA, SHINGRIX, UBRELVY, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error